Benefits
Acute diarrhea treatment
B. clausii reduces duration and severity of acute diarrhea in children and adults across multiple randomized trials. Effect sizes are moderate; benefits seen within days of starting supplementation. One of the better-evidenced uses for this strain.
Antibiotic-associated diarrhea prevention
Taken alongside antibiotic therapy, B. clausii reduces the incidence of antibiotic-associated diarrhea. Heat-stable spore form means it survives stomach acid intact and isn't killed by concurrent antibiotic doses — unlike lactic acid bacteria probiotics.
H. pylori eradication adjunct
Used alongside standard triple therapy for H. pylori infection, B. clausii reduces side effects of antibiotic therapy and may improve patient compliance. Adjunct support; not standalone treatment.
Recurrent respiratory infections in children
Trials in children with recurrent respiratory infections show reduced infection frequency with B. clausii supplementation over months. Reflects gut-immune axis effects extending beyond GI applications.
Spore-form survival advantage
The spore form is heat-stable and acid-resistant, surviving stomach acid intact to germinate in the small intestine. Distinguishing mechanism — most probiotic forms require refrigeration and significant doses to compensate for stomach acid loss.
Allergic rhinitis support
Some clinical evidence in pediatric allergic rhinitis suggests B. clausii may reduce symptoms over weeks of use. Effects are modest and not the strongest application, but consistent with broader gut-immune modulation.
Antimicrobial peptide production
B. clausii produces antimicrobial peptides (bacteriocins) active against pathogenic bacteria. Mechanism contributes to its acute diarrhea benefits and provides plausible biological rationale for its decades of clinical use.
Decades-long safety record
Marketed in Europe and emerging markets since the 1950s with extensive real-world safety data across millions of users. GRAS status and well-tolerated even in young children and immunocompromised patients.
Mechanism of action
Intrinsic polyantibiotic resistance (uniquely positioned)
Natural genetic resistance to multiple antibiotic classes — distinct from acquired resistance via plasmid transfer. Allows the probiotic to survive and exert effects during concurrent antibiotic therapy, the central practical advantage for AAD prevention.
Spore-forming durability
Bacterial endospores are dormant, resistant structures surviving heat, acid, bile, and processing. Spores germinate to active vegetative cells in the small intestine where they exert effects.
Antimicrobial peptide production
B. clausii produces antimicrobial peptides active against C. difficile and other opportunistic pathogens. Direct competitive antimicrobial mechanism beyond niche occupation.
Microbiota restoration during dysbiosis
During antibiotic-induced dysbiosis, B. clausii occupies niche space and supports recovery of native commensals. Mechanism for reduced AAD development.
Anti-inflammatory effects
Reduces pro-inflammatory cytokine production in the gut mucosa — supporting recovery from inflammatory diarrhea episodes.
Clinical trials
PMC12182463 — systematic review and meta-analysis of 11 RCTs plus 3 non-randomized controlled trials in pediatric acute gastroenteritis. B. clausii vs ORT (with or without zinc): shortened diarrhea duration, reduced stool number, shortened hospital stay. Methodologically robust with multiple country populations — among the strongest probiotic evidence bases for pediatric gastroenteritis.
Infect Dis Ther 2020 — randomized double-blind 130-patient phase IIIB study during H. pylori eradication therapy in Italy. B. clausii 1 capsule three times daily for 2 weeks. Week-1 diarrhea incidence 29% vs 48% placebo (RR 0.61, 95% CI 0.39-0.97, p=0.03). 19% absolute risk reduction in adult AAD prevention.
Phase 3 RCT in 6-month-to-5-year-old children with acute moderate diarrhea, using ORT + zinc + B. clausii. Indian pediatric population evidence supplementing the global trial base.